Antares Pharma files U.S. marketing application for drug-device testosterone combo; shares ahead 5% premarket

• Antares Pharma (ATRS) is up 5% premarket, albeit on only 600 shares, in response to its announcement that it has submitted a New Drug Application (NDA) to the FDA seeking approval of QuickShot Testosterone, a drug-device combination product that delivers a subcutaneous dose of testosterone via an auto injector, for the treatment of men with low testosterone (hypogonadism).
• The company says it is the first product designed for the subcutaneous delivery of testosterone through a fine gauge needle.